Interferon-α2b restores the impaired chemotactic activity of peripheral blood mononuclear cells from head and neck squamous cell carcinoma patients by modulating CXC receptor ligand interaction

Journal of Interferon and Cytokine Research

Volumn 28, Issue 8, 2007, Pages 487-499

  Chakraborty, Krishnendu ^a   Bose, Anamika ^a   Pal, Smarajit ^a   Chattopadhyay, Utpala ^b   Baral, Rathindranath ^a  

^a CHITTARANJAN NATIONAL CANCER INSTITUTE   (India)

^b UNIVERSITY OF CALCUTTA   (India)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2B INTERFERON; CHEMOKINE RECEPTOR CXCR3; CXCL9 CHEMOKINE; GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; SHANFERON; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; CXCL10 PROTEIN, HUMAN; CXCL9 PROTEIN, HUMAN; CXCR3 PROTEIN, HUMAN;

ARTICLE; CANCER CELL CULTURE; CELL MIGRATION; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFECT; FEMALE; HEAD AND NECK CARCINOMA; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOMODULATION; MALE; NEUTROPHIL CHEMOTAXIS; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; SQUAMOUS CELL CARCINOMA; ADULT; ALTERNATIVE RNA SPLICING; CELL STRAIN K 562; CELL STRAIN U937; CHEMOTAXIS; GENE EXPRESSION REGULATION; HEAD AND NECK TUMOR; LEUKEMIA CELL LINE; METABOLISM; MIDDLE AGED; MONONUCLEAR CELL; SECRETION;

ADULT; ALTERNATIVE SPLICING; ANTINEOPLASTIC AGENTS; CHEMOKINE CXCL10; CHEMOKINE CXCL9; CHEMOTAXIS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HEAD AND NECK NEOPLASMS; HUMANS; INTERFERON ALFA-2B; INTERFERON TYPE II; JURKAT CELLS; K562 CELLS; LEUKOCYTES, MONONUCLEAR; MALE; MIDDLE AGED; NEOPLASMS, SQUAMOUS CELL; RECEPTORS, CXCR3; U937 CELLS;

EID: 50249179152     PISSN: 10799907     EISSN: None     Source Type: Journal    
DOI: 10.1089/jir.2008.0001     Document Type: Article

References (21)

1. Baggiolini M. 1998. Chemokines and leukocyte traffic. Nature 392:565-568.
2. Bauchereau J, Briere F, Caux C, Davoust J, Lebecque S, Liu YJ, Pulendran B, Palucka K. 2000. Immunobiology of dendritic cells. Annu Rev Immunol 18:767-711.
3. Belardelli F, Ferrantini M, Proietti E, Kirkwood JM. 2002. Interferon-alpha in tumor immunity and immunotherapy. Cytokine Growth Factor Rev 13:119-134.
4. Bose A, Baral RN. 2007. IFNα2b stimulated release of IFNγ differentially regulates T cell and NK cell mediated tumor cell cytotoxicity. Immunol Lett 108:68-77.
5. Bose A, Ghosh D, Pal S, Mukherjee KK, Biswas J, Baral RN. 2006. Interferon α2b augments suppressed immune functions in tobacco related head and neck squamous cell carcinoma patients by modulating cytokine signaling. Oral Oncol 42:161-171.
6. Chen Z, Malhotra PS, Thomas GR, Ondrey FG, Duffey DL, Smith CW, Enamorado I, Yeh NT, Kroog GS, Rudy S, McCullagh L, Mousa S, Quezado M, Herscher LL, Van Waes C. 1999. Expression of proinflammatory and proangiogenic cytokines in patients with head and neck cancer. Clin Cancer Res 5:1369-1379.
7. Datta D, Flaxenburg JA, Laxmanan S, Geehan C, Grimm M, Waaga-Gasser AM, Briscoe DM, Pal S. 2006. Ras-induced modulation of CXCL10 and its receptor splice variant CXCR3-B in MDA-MB-435 and MCF-7 cells: relevance for the development of human breast cancer. Cancer Res 66:9509-9518.
8. Feferman T, Maiti PK, Berrih-Aknin S, Bismuth J, Bidault J, Fuchs S, Souroujon, MC. 2005. Overexpression of IFN-induced protein 10 and its receptor CXCR3 in myasthenia gravis. J Immunol 174:5324-5331.
9. Glaser J, Gonzalez R, Perreau VM, Cotman CW, Keirstead HS. 2004. Neutralization of the chemokine CXCL10 enhances tissue sparing and angiogenesis following spinal cord injury. J Neurosci Res 77:701-708.
10. Goldberg-Bittman I, Neumark E, Sagi-assif O, Azenshtein E, Meshel T, Witz IP, Ben-Baruch A. 2004. The expression of chemokine receptor CXCR3 and its ligand CXCL10 in human breast adenocarcinoma cell lines. Immunol Lett 92:171-178.
11. Kelsen SG, Aksoy MO, Yang Y, Shahabuddin S, Litvin J, Safadi F, Rogers TJ. 2004. The chemokine receptor CXCR3 and its splice variant are expressed in human airway epithelial cells. Am J Physiol Lung Cell Mol Physiol 287:L584-L591.
12. Lasagni L, Francalanci M, Annunziato F, Lazzeri E, Giannini S, Cosmi L, Sagrinati C, Mazzinghi B, Orlando C, Maggi E, Marra F, Romagnani S, Serio M, Romagnani P. 2003. An alternatively spliced variant of CXCR3 mediated the inhibition of endothelial cell growth induced by IP-10, Mig, and I-TAC, and acts as functional receptor for platelet factor 4. J Exp Med 197:1537-1549.
13. Liu YQ, Poon RT, Hughes J, Li QY, Yu WC, Fan ST. 2005. Desensitization of T lymphocytes function by CXCR3 ligands in human hepatocellular carcinoma. World J Gastroenterol 11:164-170.
14. Moser B, Loetscher P. 2001. Lymphocyte traffic control by chemokines. Nat Immunol 2:123-140.
15. Okamoto M, Kawabe T, Iwasaki Y, Hara T, Hashimoto N, Imaizumi K, Hasegawa Y, Shimokata K. 2005. Evaluation of interferon-gamma, interferon-gamma-inducing cytokines, and interferon-gamma-inducible chemokines in tuberculous pleural effusions. J Lab Clin Med 145:88-93.
16. + effector T cells. J Leukoc Biol 71:669-676.
17. Romagnani P, Lasagni L, Annunziato F, Serio M, Romagnani S. 2004. CXC chemokines: the regulatory link between inflammation and angiogenesis. Trends Immunol 25:201-209.
18. Strieter RM, Belperio JA, Burdick MD, Keane MP. 2005. CXC chemokines in angiogenesis relevant to chronic fibroproliferation. Curr Drug Targets Inflamm Allergy 4:23-26.
19. Taub DD, Longo DL, Murphy WJ. 1996. Human interferon-inducible protein-10 induces mononuclear cell infiltration in mice and promotes the migration of human T lymphocytes into the peripheral tissues and human peripheral blood lymphocytes- SCID mice. Blood 87:1423-1433.
20. Vollmer J, Jurk M, Samulowitz U, Lipford G, Forsbach A, Wullner M, Tluk S, Hartmann H, Kritzler A, Muller C, Schetter C, Krieg AM. 2004. CpG oligodeoxynucleotides stimulate IFN-gamma-inducible protein-10 production in human B cells. J Endotoxin Res 10:431-438.
21. Zlotnik A, Yoshie O. 2000. Chemokines: a new classification system and their role in immunity. Immunity 12:121-127.